Rosiglitazone plus metformin: combination therapy for Type 2 diabetes

Bibliography

• ZIMMET P, ALBERTI KG, SHAW J: Global and societal implications of the diabetes epidemic. iNature i (2001) 414:782–787.
   PubMed Web of Science ®Google Scholar
• SKYLER JS, ODDO C: Diabetes trends inthe USA. iDiabetes Metab. Res. Rev. i (2002) 18\(Suppl. 3):S21–S26.
   Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). iLancet i (1998) 352:837–853.
   PubMed Web of Science ®Google Scholar
• THE DCCT REPORT: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. iN Engl. I Med. i (1993) 329:977–986.
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. iCirculation i (2002) 106:3143–3421.
   PubMed Web of Science ®Google Scholar
• ••The most recent guidelines formanagement of dyslipidaemia, includes diagnostic criteria for the metabolic syndrome.
   Google Scholar
• GROOP LC, SALORANTA C, SHANK M, BONADONNA RC, FERRANNINI E, DEFRONZO RA: The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and noninsulin-dependent diabetes mellitus. iClin. Endocrinol. Metab. i (1991) 72:96–107.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). iLancet i (1998) 352:854–865.
   PubMed Web of Science ®Google Scholar
• VAN GAAL LF, DE LEEUW IH: Rationale and options for combination therapy in the treatment of Type 2 diabetes. iDiabetologia i (2003) 46\(Suppl. 1):M44–M50.
   Google Scholar
• INZUCCHI SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. iJAM i (2002) 287:360–372. .
   Google Scholar
• •Review on the treatment of Type 2 diabetes with oral agents.
   Google Scholar
• DEFRONZO RA: Pharmacologic therapy for type 2 diabetes mellitus. iAnn. Intern. Med. i (1999) 131:281–303.
   PubMed Web of Science ®Google Scholar
• •An extensive review on the treatment of Type 2 diabetes.
   Google Scholar
• INZUCCHI SE, MAGGS DG, SPOLLETT GR iet al.: i Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. iN Engl. I Med. i (1998) 338:867–872.
   Google Scholar
• WAGSTAFF AJ, GOA KL: Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. iDrugs i (2002) 62: 1805-1837.
   Google Scholar
• •A review on rosiglitazone.
   Google Scholar
• GIANNARELLI R, ARAGONA M, COPPELLI A, DEL PRATO S: Reducing insulin resistance with metformin: the evidence today. iDiabetes Metab. i (2003) 29(4 Pt 2):6528–6535.
   Google Scholar
• GlaxoSmithKline: Avandamet® (rosiglitazone maleate and metformin hydrochloride) prescribing information. GlaxoSmithKline, Research Triangle Park, NC 27709, USA (2003).
   Google Scholar
• Bristol-Myers Squibb: Glucophage® (metformin hydrochloride tablets 500 and 850 mg) prescribing information. Bristol-Myers Squibb, Princeton, NJ, USA (1997).
   Google Scholar
• LEBOVITZ HE: Differentiating members of the thiazolidinedione class: a focus on safety. iDiabetes Metab. Res. Rev i (2002) 18\(Suppl. 2):S23–S29.
   Google Scholar
• MIYAZAKI Y, GLASS L, TRIPLITT C iet al: i Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. iDiabetologia i (2001) 44:2210–2219.
   PubMed Web of Science ®Google Scholar
• MATTHAEI S, STUMVOLL M, KELLERER M, HARING HU: Pathophysiology and pharmacological treatment of insulin resistance. iEndocc Rev i (2000) 21:585–618.
   Google Scholar
• •A review on insulin-sensitising agents.
   Google Scholar
• STUMVOLL M: Thiazolidinediones - some recent developments. iExpert Opin. Investig. Drugs. i (2003) 12:1179–1187.
   PubMed Web of Science ®Google Scholar
• YOUNG PW, BUCKLE DR, CANTELLO BC iet al.: i Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. iPharmacol. Exp. Titer. i (1998) 284:751–759.
   Google Scholar
• KAHN CR, CHEN L, COHEN SE: Unraveling the mechanism of action of thiazolidinediones. iClin. Invest. i (2000) 106:1305–1307.
   PubMed Web of Science ®Google Scholar
• STUMVOLL M, HARING HU: Glitazones: clinical effects and molecular mechanisms. iAnn. Med. i (2002) 34:217–224.
   Google Scholar
• MIYAZAKI Y, HE H, MANDARINO LJ, DEFRONZO RA: Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. iDiabetes i (2003) 52: 1943-1950.
   Google Scholar
• HALLSTEN K, VIRTANEN KA, LONNQVIST F iet al: i Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. iDiabetes i (2002) 51:3479–3485.
   PubMed Web of Science ®Google Scholar
• CAREY DG, COWIN GJ, GALLOWAY GJ iet al.: i Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. iObes. Res. i (2002) 10:1008–1015.
   Google Scholar
• MAYERSON AB, HUNDAL RS, DUFOUR S iet al.: i The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. iDiabetes i (2002) 51:797–802.
   Google Scholar
• JUHL CB, HOLLINGDAL M, PORKSEN N, PRANGE A, LONNQVIST F, SCHMITZ 0: Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. iClin. Endocrinol Metab. i (2003) 88:3794–3800.
   PubMed Web of Science ®Google Scholar
• LEBOVITZ HE, DOLE JF, PATWARDHIAN R, RAPPORT EB, FREED MI: Rosiglitazone Clinical Trials Study Group. I iClin. Endocrinol Metab. i (2001) 86:280–288.
   PubMed Web of Science ®Google Scholar
• CHARBONNEL B, LONNQVIST F, JONES NP, ABEL MG, PATWARDDHAN: Rosiglitazone is superior to glyburide in reducing fasting plasma glucose after 1 yar of treatment in type 2 diabetic patients. iDiabetes i (1999) 48\(Suppl. 1):A114.
   Google Scholar
• PORTER LE, FREED MI, JONES NP, BISWAS N: Rosiglitazone reduces proinsulin/insulin ratio and improves I3-cell function in type 2 diabetes. iDiabetologia i (2000) 43\(Suppl. 1):A192.
   Google Scholar
• LUPI R, DEL GUERRA S, MARSELLI L iet al.: i Rosiglitazone prevents the impairment of human islet function induced by fatty-acids. Evidence for a role PPAR-fgammal2 in the modulation of insulin secretion. iAm. j Physic] Endocrinol Metab. i (2004) 286(4):E560–E567(Epub 2003 Nov 18).
   Google Scholar
• •Novel data on potential protection of human islets from lipotoxicity.
   Google Scholar
• RICOTE M, HUANG J, FAJAS L iet al.: iExpression of the perwdme proliferators-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. iNatl. Acad. Sci. USA i (1998) 95:7614–7619.
   Google Scholar
• MARX N, BOURCIER T, SURKHOVA GK, LIBBY P, PLUTZKY J: PPARy activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression PPARy as a potential mediator in vascular disease. iArteriosc/er. Thrornb. Vase. Biol. i (1999) 19:546–551.
   PubMed Web of Science ®Google Scholar
• LAW RE, GOETZE S, XI XP iet al: i Expression and function of PPARy in rat and Human vascular smooth muscle cells. iCirculation i (2000)101:1311–1318.
   PubMed Web of Science ®Google Scholar
• PATEL NG, HOLDER JC, SMITH SA, KUMAR S, EGGO MC: Differential regulation of lipogenesis and leptin production by independent signaling pathways and rosiglitazone during human adipocyte differentiation. iDiabetes i (2003) 52:43–50.
   PubMed Web of Science ®Google Scholar
• NEUSCHWANDER-TETRI BA, BRUNT EM, WEHMEIER KR, OLIVER D, BACON BR: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. iHepatology i (2003) 38:1008–1017.
   Google Scholar
• BAKRIS G, VIBERTI G, WESTON WM, HEISE M, PORTER LE, FREED MI: Rosiglitazone reduces urinary albumin excretion in type II diabetes. iHum. Hypertens. i (2003) 17:7–12.
   PubMed Web of Science ®Google Scholar
• PISTROSCH F, PASSAUER J, FISCHER S, FUECKER K, HANEFELD M, GROSS P: In Type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. iDiabetes Care i (2004) 27:484–490.
   PubMed Web of Science ®Google Scholar
• CHOI SH, CHOI DH, KO YK iet al.: i Preventing effects of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. iDiabetes i (2003) 52\(Supp1.1):A19.
   Google Scholar
• RYAN MJ, DIDION SP, MATHUR S, FARACI FM, SIGMUND CD: PPARIgammal agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. iHypertension i (2004) 43(3):661–666.
   Google Scholar
• SHARGORODSKY M, WAINSTEIN G, GAVISH E, LEIBOVITZ Z, MATAS D, ZIMLICHMAN R: Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. iAm. J. Hypertens. i (2003) 16:617–622.
   PubMed Web of Science ®Google Scholar
• RAJI A, SEELY EW, BEKINS SA, WILLIAMS GH, SIMONSON DC: Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. iDiabetes Care i (2003) 26:172–178.
   PubMed Web of Science ®Google Scholar
• HARTE AL, MCTERNAN PG, MCTERNAN CL, SMITH SA, BARNETT AH, KUMAR S: Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. iDiabetes Obes. Metab. i (2003) 5:302–310.
   PubMed Web of Science ®Google Scholar
• YKI-JARVINEN H, SUTINEN J, SILVEIRA A iet al.: i Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. iilrteriosc/er. Thrornb. Vase. Biol. i (2003) 23:688–694.
   Google Scholar
• HAFFNER SM, GREENBERG AS, WESTON WM, CHEN H, WILLIAMS K, FREED MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. iCirculation i (2002) 106:679–684.
   PubMed Web of Science ®Google Scholar
• •Describes potential effects of rosiglitazone on inflammatory markers associated with an increased risk of CVD.
   Google Scholar
• SIDHU JS, COWAN D, KASKI JC: The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. iJ. Am. Coll Cardiol i (2003) 42:1757–1763.
   PubMed Web of Science ®Google Scholar
• MARX N, IMHOF A, FROEHLICH J iet al.: i Effect of rosiglitazone treatment on soluble CD4OL in patients with Type 2 diabetes and coronary artery disease. iCirculation i (2003) 107:1954–1957.
   Google Scholar
• YANG W-S, JENG CY, VVU TJ iet al.: i Syntetic pendsome proliferator-activated receptor-y agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. iDiabetes Care i (2002) 25:376–380.
   Google Scholar
• FREED MI, RATNER R, MARCOVINA SM iet al.: i Effects of rosiglitazone alone and in combination with atorvastatin on metabolic abnormalities in type 2 diabetes mellitus. iAm. J. Cardiol i (2002) 90:947–952.
   Google Scholar
• KO SH, SONG KH, AHN YB iet al: i The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus. iMetabolism i (2003) 52:731–734.
   PubMed Web of Science ®Google Scholar
• SUTINEN J, HAKKINEN AM, WESTERBACKA J iet al.: i Rosiglitazone in treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. iAntivir. Titer: i (2003)52:731–734.
   Google Scholar
• VIBERTI GC: Rosiglitazone: potential beneficial impact on cardiovascular disease. iInt. J. Chit. Piaci i (2003) 57:128–134.
   PubMed Web of Science ®Google Scholar
• CUSI K, DEFRONZO RA: Metformin: a review of its metabolic effects. iDiabetes Rev i (1998) 6:89–131.
   Google Scholar
• HUNDAL RS, INZUCCHI SE: Metformin: new understandings, new uses. iDrugs i (2003) 63:1879–1894.
   PubMed Web of Science ®Google Scholar
• •A broader view on the potential use of metformin for the treatment of human disesases.
   Google Scholar
• RADZIUK J, BAILEY CJ, WIERNSPERGER NF, YUDKIN JS: Metformin and its liver targets in the treatment of type 2 diabetes. iCurl: Drug i Targets Immune Endocr. Metabol Disord. (2003) 3:151–169.
   Google Scholar
• FERY F, PLAT L, BALASSE EO: Effects of metformin on the pathways of glucose utilization after oral glucose in non-insulin-dependent diabetes mellitus patients. iMetabolism i (1997) 46:227–233.
   PubMed Web of Science ®Google Scholar
• LEVERVE XM, GUIGAS B, DETAILLE D iet al.: i Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. iDiabetes Metab. i (2003) 29(4 Pt 2):6S88-6S94.
   Google Scholar
• FLECHTNER-MORS M, DITSCHUNEIT HH, JENKINSON CP, ALT A, ADLER G: Metformin inhibits catecholamine-stimulated lipolysis in obese, hyperinsulinemic, hypertensive subjects in subcutaneous adipose tissue: an in situ microdialysis study. iDiabetes Med. i (1999) 16(12):1000–1006.
   PubMed Web of Science ®Google Scholar
• RICCIO A, DEL PRATO S, VIGILI DE KREUTZENBERG S, TIENGO A: Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin. iDiabetes Metab. i (1991) 17(1 Pt 2):180–184.
   Google Scholar
• ZHOU G, MYERS R, LI Y iet al: i Role of AMP-activated protein kinase in mechanism of metformin action. iClin. Invest. i (2001) 108:1167–1174.
   PubMed Web of Science ®Google Scholar
• CORTON JM, GILLESPIE JG, HAWLEY SA, HARDIE DG: 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? iEur.j Biochem. i (1995) 229:558–565.
   Google Scholar
• WITTERS LA: The blooming of the French lilac. iJ. Clin. Invest. i (2001) 108:1105–1057.
   PubMed Web of Science ®Google Scholar
• LUPI R, DEL GUERRA S, TELLINI C iet al.: i The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. iEur. Pharmacol i (1999) 364:205–209.
   Google Scholar
• LUPI R, DEL GUERRA S, FIERABRACCI V iet al.: i Lipotoxicity in human pancreatic islets and the protective effect of metformin. iDiabetes i (2002) 51\(Suppl. 1):5134–5137.
   Google Scholar
• ABBASI F, CHU JW, MCLAUGHLIN T, LAMENDOLA C, LEARY ET, REAVEN GM: Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. iMetabolism i (2004) 53:159–164.
   PubMed Web of Science ®Google Scholar
• •Recent data supporting a positive effect of metformin in improving the CVD risk-profile in Type 2 diabetic patients.
   Google Scholar
• MAMPUTU JC, WIERNSPERGER NE RENTER G: Antiatherogenic properties of metformin: the experimental evidence. iDiabetes Metab. i (2003)\29(4 Pt 2):6571–6576.
   Google Scholar
• DESPRES JP: Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. iDiabetes Metab. (2003) i 29(4 Pt 2):6553–6561.
   Google Scholar
• BEISSWENGER P, RUGGIERO-LOPEZ D: Metformin inhibition of glycation processes. iDiabetes Metab. i (2003) 29(4 Pt 2):6595–65103.
   Google Scholar
• FRANCESCHINI G, PAOLETTI R: Drugs controlling triglyceride metabolism. iMed. Res. Rev i (1993) 13:125–138.
   PubMed Web of Science ®Google Scholar
• GRANT P: Beneficial effects of metformin on haemostasis and vascular function in man. iDiabetes Metab. i (2003)29(4 Pt 2):6544–6552.
   Google Scholar
• GIUGLIANO D, DE ROSA N, DI MARO G iet al.: i Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. iDiabetes Care i (1993) 16:1387–1390.
   Google Scholar
• DORELLA M, GIUSTO M, DA TOS V iet al.: i Improvement of insulin sensitività by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance. iClin. Endocrinol Metab. i (1996) 81:1568–1574.
   Google Scholar
• COX PJ, RYAN DA, HOLLIS FJ iet al.: i Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. iDrug Metab. Dispos. i (2000) 28:772–780.
   Google Scholar
• TUCKER GT, CASEY C, PHILLIPS PJ, CONNOR H, WARD JD, WOODS HF: Metformin kinetics in healthy subjects and in patients with diabetes mellitus. iBr. Clin. Pharmacol i (1981) 12:235–246.
   PubMed Web of Science ®Google Scholar
• SIRTORI CR, FRANCESCHINI G, GALLI-KIENLE M iet al.: i Disposition of metformin (N,N-dimethylbiguanide) in man. iClin. Pharmacol Ther. i (1978) 24:683–693.
   PubMed Web of Science ®Google Scholar
• BALDWIN SJ, CLARKE SE, CHENERY RJ: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. iBr. J. Clin. Pharmacol i (1999) 48:424–432.
   PubMed Web of Science ®Google Scholar
• PATERL BR, DIRINGER K, CONRAD J iet al.: i Population pharmacokinetics of rosiglitazone in phase III clinical trials. iClin. Pharmacol Titer. i (2000) 67:123 (Abstract PII–33).
   Google Scholar
• SAMBOL NC, CHIANG J, LIN ET iet al: i Kidney function and age are both predictors of pharmacokinetics of metformin. iClin. Pharmacol i (1995) 35:1094–1102.
   PubMed Web of Science ®Google Scholar
• FONSECA V, ROSENSTOCK J, PAT WARDHAN R, SALZMAN A: Effect of metformin and rosiglitazone combination therapy in patients with Type 2 diabetes mellitus: a randomized controlled iJAMA i (2000) 283: 1695-1702.
   Google Scholar
• •Efficacy and safety data of rosiglitazone/metformin in Type 2 diabetic patients.
   Google Scholar
• GOMEZ-PEREZ FJ, FANGHANEL-SALMON G, BARBOSA JA iet al.: i Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. iDiabetes Metab. Res. Rev i (2002) 18:127–134.
   Google Scholar
• •Efficacy and safety data of rosiglitazone/metformin in Mexican-American Type 2 diabetic patients.
   Google Scholar
• JONES TA, SUTTER M, VAN GAAL LF, JONES NP: Adddition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. iDiabetes Obes. Metab. i (2003) 5:163–170.
   PubMed Web of Science ®Google Scholar
• •A ipost hoc i analysis of efficacy and safety of rosiglitazone/metformin in Type 2 diabetic patients according to their BMI.
   Google Scholar
• BALLARY C, DESAI A: Drug trial report: efficacy and safety of combination of metformin and rosiglitazone in patients with Type 2 diabetes mellitus. A postmarketing study. iJAMA i (2003) 101:1–5.
   Google Scholar
• •Post-marketing surveillance on efficacy and safety of rosiglitazone/metformin in Indian Type 2 diabetic patients.
   Google Scholar
• POULSEN MK, HENRIKSEN JE, HOTHER-NIELSEN 0, BECK-NIELSEN H: The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. iDiabetes Care i (2003) 26:3273–3279.
   PubMed Web of Science ®Google Scholar
• • Rosiglitazone/metformin and insulin therapy: efficacy and safety data on triple combination therapy.
   Google Scholar
• ROSNSTOCK J, GOLDSTEIN B, WOODDEL M, STROW LJ, WATERHOUSE R, COBITZ AR: Study 284 (EMPIRE) Greater benefits of rosiglitazone (RSG) added to submaximal dose of metformin (MET) compared to maximizing metformin dose in type 2 diabetes mellitus (T2DM) patients. iDiabetes i (2004) 53:A.
   Google Scholar
• WOLFFENBUTTEL BH, GOMIS R, SQUATRITO S, JONES NP, PAT WARDHAN RN: Addition of low-dose rosiglitazone to sulphanylurea therapy improve glycemic control in Type 2 diabetic patients. iDiabet Med. i (2000) 17(1):40–47.
   Google Scholar
• ROSENSTOCK J, PORTER MA, HEISE,O'NEILL MC, KRAVITZ B, FREED MI, THE ROSIGLITAZONE 135 STUDY GROUP: Type 2 diabetes in the elderly: reaching durable glycemic goals with combination sulfonalnylurea and rosiglitazone. iDiabetes Metab. i (2003) 29:S247–S248.
   Google Scholar
• HAMMAN A, MATTHAEL S, MAUERSBERGER H iet al.: i Efficacy and safety of rosiglitazone in combination with glimperide. iDiabetes Metab. i (2003) 29:4S249.
   Google Scholar
• NESTO RW, BELL D, BONOW RO iet al: i Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from American Heart Association and American Diabetes Association. iDiabetes Care i (2004) 27:256–263.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline: Avandia® (rosiglitazone maleate) package insert. GlaxoSmithKline, Philadelphia, PA, USA 2000.
   Google Scholar
• MAGGIO CA, PI-SUNYER FX: Obesity and type 2 diabetes. iEndocrinol. Metab. Clin. North Am. i (2003) 32(4):805–822.
   PubMed Web of Science ®Google Scholar
• BRAY GA: Risks of obesity. iEndocrinol. Metab. Clin. North Am. i (2003) 32:787–804.
   PubMed Web of Science ®Google Scholar
• MELIKIAN C, WHITE TJ, VANDERPLAS A, DEZII CM, CHANG E: Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. iClin. Thec i (2002) 24:460–467.
   PubMed Web of Science ®Google Scholar
• TURNER RC, CULL CA, FRIGHI V, HOLMAN RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. iJAMA i (1999) 281:2005–2012.
   Google Scholar
• DEL GUERRA S, LUPI R, MARSELLI L iet al.: i Metformin ameliorates function and survival of pancreatic islets isolated from Type 2 diabetic patients. iDiabetologia i (2003) 46\(Suppl 2):A169.
   Google Scholar
• FINEGOOD DT, MCARTHUR MD, KOJWANG D iet al: i Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. iDiabetes i (2001) 50:1021–1029.
   Google Scholar
• BELL DS: Beta-cell rejuvenation with thiazolidinediones. iAm. J. Med. i (2003) 115 (Suppl 8A):205-235. Affiliation Stefano Del Pratot & Laura Volpe tAuthor for correspondence Department of Endocrinology and Metabolism, Section of Diabetes, Ospedale Cisanello, Via Paradisa, 2, 56124 Pisa, Italy Tel: +39 050 995103; Fax: +39 050 541521; E-mail: [email protected]
   Google Scholar